Impact of Tyrosine Kinase Inhibitors and Co-medications on the Efficacy of Patients with Advanced Non-small Cell Lung Cancer

• Main Authors: Ting-Yu Huang, 黃亭瑜
• Other Authors: Yueh-Ching Chou
• Format: Others
• Language: zh-TW
• Published: 2018
• Online Access: http://ndltd.ncl.edu.tw/handle/39dv28

碩士 === 國立陽明大學 === 藥理學研究所 === 106 === Tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib are recommended as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating mutations. Gefitinib, erlotinib, and afatinib have been reimbursed by the National Health Insurance program for the first-line treatment of patients with stage IIIb or IV NSCLC with EGFR-activating mutations now. However, few studies compared these three TKIs together. Besides, previous studies showed specific medications such as hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), metformin, acid-suppressing (AS) medications, and glucocorticoids might influence efficacy of TKIs. There was few large sample and well-conducted studies to confirm the impact of co-medications. Thus, we conducted a retrospective study using database of Taipei Veterans General Hospital to determine the efficacy of TKIs and impact of co-medications on survival.